Course in parkinson disease subtypes: A 39-year clinicopathologic study

Neurology

Volumn 73, Issue 3, 2009, Pages 206-212

  Rajput, A H ^a,b   Voll, A ^c   Rajput, M L ^b   Robinson, C A ^b   Rajput, A ^b  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b SASKATOON HEALTH REGION   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUTOPSY; CLINICAL STUDY; CROSS-SECTIONAL STUDY; DEMENTIA; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; FOLLOW UP; GROUPS BY AGE; HOEHN AND YAHR SCALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ONSET AGE; PARKINSON DISEASE; PATHOLOGY; PRIORITY JOURNAL; SCORING SYSTEM; TREMOR; AKINETIC MUTISM; BRAIN; BRAIN LEVEL; CLASSIFICATION; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; MUSCLE RIGIDITY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME;

AGE OF ONSET; AGED; AGED, 80 AND OVER; AKINETIC MUTISM; AUTOPSY; BRAIN; BRAIN CHEMISTRY; COHORT STUDIES; COMORBIDITY; DEMENTIA; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUSCLE RIGIDITY; PARKINSON DISEASE; TIME FACTORS; TREMOR;

EID: 68949194368     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181ae7af1     Document Type: Article

References (40)

1. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease. Arch Neurol 2002;59: 1724-1728.
2. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
3. Roos RAC, Jongen JCF, Van der Velde EA. Clinical course of patients with idiopathic Parkinson's disease. Mov Disord 1996;11:236-242.
4. 4. Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B. Clinical characteristics in early Parkinson's disease in a central California population-based study. Mov Disord 2005;20:1133-1142. (Pubitemid 41632200)
5. 5. Lewis SJG, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005;76:343-348. (Pubitemid 40299121)
6. 6. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006;21:11231130. (Pubitemid 44336596)
7. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001;58:1611-1615.
8. GeIb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
9. 9. Hilker R Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-382. (Pubitemid 40349472)
10. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sei 1991;18:275-278.
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
12. Burke RE, Dauer WT, Vonsattel JPG. A critical evaluation of the Braak Staging Scheme for Parkinson's disease. Ann Neurol 2008;64:485-491.
13. Rajput AH, Sitte H, Rajput A, Fenton ME, Pifl C, Hornykiewicz O. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 2008;70:1403-1410.
14. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
15. Rajput AH, Uitti RJ, Rajput AH, Offord KP. Timely levodopa (LD) administration prolongs survival in Parkinson's disease. Parkinsonism Relat Disord 1997;3:159-165.
16. 16. Rajput AH, Stern W, Laverty WH. Chronic low dose therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984;34:991-996. (Pubitemid 14094234)
17. 17. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996;46:1551-1556. (Pubitemid 26185770)
18. Webster DD. Critical analysis of disability in Parkinson's disease. Mod Treat 1968;5:257-282.
19. Fahn S, Elton RL, UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-305.
20. Rajput AH, Fenton ME, Birdi S, et al. Clinicalpathological study of levodopa complications. Mov Disord 2002;17:289-296.
21. Rajput AH, Rozdilsky B, Rajput A, Ang L. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol 1990;13:553-558.
22. Martinez-Martin P, Tolosa E, Hernandez B, Badia X, ValidQUICK Study Group. Validation of the "QUICK" Questionnaire: a tool for diagnosis of "wearing-off " in patients with Parkinson's disease. Mov Disord 2008;23:830-836.
23. 23. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorder Society Task Force. Mov Disord 2007;22:2314-2324. (Pubitemid 351155975)
24. 24. Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P. Reversible drug-induced parkinsonism: clinicopathologic study of two cases. Arch Neurol 1982; 39:644-646. (Pubitemid 12009439)
25. 25. Goetz CG, Tanner CM, Stebbins GT, Buchman AS. Risk factors for progression in Parkinson's disease. Neurology 1988;38:1841-1844. (Pubitemid 19004576)
26. Ferguson LW, Rajput ML, Muhajarine N, Shah AM, Rajput A. Clinical features at first visit and rapid disease progression in Parkinson's disease. Parkinsonism Relat Disord 2008;14:431-435.
27. Hely MA, Morris JGL, Reid WGJ, Trafficante R Sydney Multicenter Study of Parkinson's Disease: non-L-doparesponsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
28. 28. Rajput AH, Pahwa R Pahwa P, Rajput A. Prognostic significance of the onset mode in parkinsonism. Neurology 1993;43:829-830. (Pubitemid 23121983)
29. Marttila RJ, Rinne UK. Progression and survival in Parkinson's disease. Acta Neurol Scand 1991;84(suppl 136):24-28.
30. 0. Gibb WR, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 1988;38:1402-1406.
31. 31. Arevalo GG, Jorge R, Garcia S, Scipioni O, Gershanik O. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. Mov Disord 1997; 12:277-284. (Pubitemid 27216123)
32. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-755.
33. 33. Schiess MC, Zheng H, Soukup VM, Bonnen JG, Nauta HJW. Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. Parkinsonism Relat Disord 2000;6:69-76. (Pubitemid 30122865)
34. Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008;7:927-938.
35. 35. Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson's disease: a prospective study. Mov Disord 2007;22:938-945. (Pubitemid 46999288)
36. HeIy MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney Multicenter Study of Parkinson's Disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.
37. Jankovic J, Rajput AH, McDermott MP, Perl DP, The Parkinson Study Group. The evolution of diagnosis in early Parkinson disease. Arch Neurol 2000;57:369-372.
38. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease? A clinicopathologic study. Neurology 1992; 42:1142-1146.
39. 39. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force Report on the Hoehn and Yahr Staging Scale: status and recommendations. Mov Disord 2004; 19: 1020-1028. (Pubitemid 39302834)
40. Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The evolution of disability in Parkinson disease. Mov Disord 2008;23:790-796.